{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"ORR is presented in this outcome measure as number of responders. Responders were those who had complete remission, partial remission and marrow response. International Consortium Proposal of Uniform Response Criteria for Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) in adults (Savona et al., 2015) was used for assessment of tumors. Tumor types evaluated include Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN).","groups":[{"description":"Participants with MDS who received study drug in part 2.","id":"OG000","title":"Part 2: Myelodysplastic Syndrome (MDS)"},{"description":"Participants with MPN who received study drug in part 2.","id":"OG001","title":"Part 2: Myeloproliferative Neoplasms (MPN)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full analysis set included all participants who received at least 1 dose of study treatment. \"Number of Participants Analyzed\" refers to participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/ death or withdrawal (maximum observation 6 years 10 months)","title":"Part 2: Overall Response Rate (ORR)-Savona 2015- Disease Indication","type":"SECONDARY","unitOfMeasure":"Participants"}